Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- Sponsors ImmusanT
- 28 Nov 2017 Results published in an ImmusanT Media Release
- 28 Nov 2017 Data from this trial was published online in EBioMedicine, an Open Access Elsevier journal supported by Cell Press and The Lancet, as reported in an ImmusanT media release.
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week